Cilostazol: A drug particularly effective for Asians?

International Journal of Stroke

Volumn 6, Issue 3, 2011, Pages 209-210

  Kim, Jong S ^a   Shinohara, Yukito ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

Author keywords

Antiplatelet; Antiplatelet therapy; Asia; Aspirin; Cerebral infarction; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CILOSTAZOL;

ARTICLE; ASIAN; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; DRUG EFFICACY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; STROKE; STROKE PATIENT; SUBARACHNOID HEMORRHAGE;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 79955772549     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00597.x     Document Type: Article

References (21)

1. Shinohara Y, Katayama Y, Uchiyama S et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9:959-68.
2. Gotoh F, Tohgi H, Hirai S et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9:147-57.
3. Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7:494-9.
4. Gorelick PHJ, Huang Y, Wong KSL ed. Epidemiology. Oxford: Wiley-Blackwell, 2008.
5. Kwon SU, Cho YJ, Koo JS et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005; 36:782-6.
6. Wong KS, Li H, Lam WW, Chan YL, Kay R. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke 2002; 33:532-6.
7. Kimura K, Kazui S, Minematsu K, Yamaguchi T. Analysis of 16, 922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 2004; 18:47-56.
8. Wu B, Lin S, Hao Z et al. Proportion, risk factors and outcome of lacunar infarction: a hospital-based study in a Chinese population. Cerebrovasc Dis 2010; 29:181-7.
9. Kim YD, Choi HY, Cho HJ et al. Increasing frequency and burden of cerebral artery atherosclerosis in Korean stroke patients. Yonsei Med J 2010; 51:318-25.
10. Shinohara Y. Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 2006; 21 (Suppl. 1): 17-24.
11. Shinohara Y, Gotoh F, Tohgi H et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008; 26:63-70.
12. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett 2009; 452:156-61.
13. Lee JH, Kim KY, Lee YK et al. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther 2004; 308:896-903.
14. Zhao D, Liu J, Wang W et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 2008; 39:1668-74.
15. Thammaroj J, Subramaniam V, Bhattacharya JJ. Stroke in Asia. Neuroimaging Clin N Am 2005; 15:273-82, ix-x.
16. Woo KS, Kim BR, Kim JE et al. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med 2010; 30:460-8.
17. Hoshino K, Horiuchi H, Tada T et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009; 73:336-42.
18. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20:153-67.
19. Shinohara Y. Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 2006; 22:57-60.
20. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169:1041-5.
21. Stone WM, Demaerschalk BM, Fowl RJ, Money SR. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. J Stroke Cerebrovasc Dis 2008; 17:129-33.